NIDDK SBIR/STTR Small Business Program
Helps NIDDK and Small Business Program for small businesses targeting diabetes.
NIDDK's Small Business Program runs the NIH SBIR and STTR mechanisms for for-profit companies building therapeutics, devices, biomarkers, imaging tools, clinical research technologies, and digital health products in diabetes, digestive, kidney, urologic, hematologic, endocrine, metabolic, nutritional, and obesity-related disease areas. It is the institute's non-dilutive route for small businesses rather than universities or nonprofits. The program covers R43/R44 SBIR and R41/R42 STTR awards, with NIDDK-specific caps of up to $350,000 in Phase I total costs, $2.2 million in Phase II, and $3 million in Phase IIB. The program is between cycles, the next standard receipt date is September 5, 2026, and NIDDK accepts SBIR clinical trials but not STTR clinical trials. The best fit is a US-registered small business with US operations and a product that fits one of NIDDK's disease areas. Strong applicants will have a clear development plan, a realistic commercialization path, and enough technical maturity to move from early proof of concept into a funded phase I or phase II program.
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.